Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.71 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.71 |
| ▸ | GRIA3 | P42263 | 5/20 | 0.71 |
| ▸ | GRIA4 | P48058 | 5/20 | 0.71 |
| ▸ | PGR | P06401 | 2/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29701185 | 1.00 | CYP1A2 (1.00) | CYP1A2MEN1KMT2ALMNATSHR | |
| SCHEMBL11807414 | 0.83 | CYP1A2 (0.70) | CYP1A2MEN1KMT2ALMNATSHR | |
| SCHEMBL6904350 | 0.80 | CYP1A2 (0.67) | CYP1A2MEN1KMT2ALMNATSHR | |
| SCHEMBL11100296 | 0.79 | MEN1 (0.66) | CYP1A2MEN1KMT2ALMNATSHR | |
| SCHEMBL11097997 | 0.79 | MEN1 (0.66) | CYP1A2MEN1KMT2ALMNATSHR | |
| SCHEMBL6910220 | 0.79 | PGR (0.72) | CYP1A2MEN1KMT2ALMNATSHR | |
| SCHEMBL6904508 | 0.79 | MEN1 (0.66) | CYP1A2MEN1KMT2ALMNATSHR | |
| SCHEMBL6799574 | 0.79 | CYP1A2 (0.65) | CYP1A2MEN1KMT2ALMNATSHR | |
| SCHEMBL7063351 | 0.79 | CYP1A2 (0.65) | CYP1A2MEN1KMT2ALMNATSHR | |
| SCHEMBL6909295 | 0.79 | CYP1A2 (0.65) | CYP1A2MEN1KMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695613-A2 | METHODS OF MODIFYING NEURONS IN VIVO TO TREAT AND/OR PREVENT AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Yale University (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2024215723-A2 | METHODS OF MODIFYING NEURONS IN VIVO TO TREAT AND/OR PREVENT AMYOTROPHIC LATERAL SCLEROSIS (ALS) | YALE UNIVERSITY (US) | 2024-10-17 | — | — | WO | claimed |
| US-20170299609-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH SK CHANNEL ACTIVATORS | WRIGHT STATE UNIVERSITY (US) | 2017-10-19 | — | — | US | claimed |
| US-20040248099-A1 | Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | US | claimed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| EP-1345618-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | Switch Biotech Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | claimed |
| WO-2002053171-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2002-07-11 | — | — | WO | claimed |
| US-4133958-A | SPLITTABLE 1,3-DIAZOLONE-2-RING | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1979-01-09 | — | — | US | claimed |
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4695613-A2 | METHODS OF MODIFYING NEURONS IN VIVO TO TREAT AND/OR PREVENT AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Yale University (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3565586-B1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024215723-A2 | METHODS OF MODIFYING NEURONS IN VIVO TO TREAT AND/OR PREVENT AMYOTROPHIC LATERAL SCLEROSIS (ALS) | YALE UNIVERSITY (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-3536783-B1 | MATERIAL FOR SCREENING COMPOUNDS ACTING ON ION CHANNELS AND USE OF SAID MATERIAL | UNIV NAGOYA CITY PUBLIC UNIV CORP (JP) | 2024-01-17 | — | — | EP | disclosed |
| CN-111670247-B | Method for preparing cancer spheroids and method for selecting colorectal cancer patients | 京诊断株式会社 | 2024-01-05 | — | — | CN | disclosed |
| US-20040248099-A1 | Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | US | disclosed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | disclosed |
| EP-1345618-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | Switch Biotech Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002053171-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2002-07-11 | — | — | WO | disclosed |
| US-4230851-A | BICYCLIC NITROGEN BASIC CONDENSATION AGENT | AGFA-GEVAERT, A.G. (DE) | 1980-10-28 | — | — | US | disclosed |
| US-4133958-A | SPLITTABLE 1,3-DIAZOLONE-2-RING | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | PBK, IL2, KCNN3 | CYP1A2 2412/4885MEN1 3761/4885KMT2A 389/4885 |
| US-20170299609-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH SK CHANNEL ACTIVATORS | KCNN3, KCNN2, KCNN1 | CYP1A2 4841/4885MEN1 4559/4885KMT2A 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.